PA
BTAI icon

Profund Advisors’s BioXcel Therapeutics BTAI Stock Holding History

Profund Advisors’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,217
Closed -$236K – 992
2023
Q2 		$236K Buy
2,217
+501
+29% +$167K 0.01% 861
2023
Q1 		$512K Buy
+1,716
New +$733K 0.03% 495

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Profund Advisors's BTAI Position: Q3 2023 in Review

Profund Advisors sold out of BioXcel Therapeutics (BTAI) in Q3 2023, closing a stake of 2,217 shares — an estimated $236K sold.

Profund Advisors first reported a position in BTAI in Q1 2023 and held it in 2 quarters. The position peaked at $512K in Q1 2023. 85 funds tracked by Wall St. Rank hold BTAI as of Q3 2023.

  • Profund Advisors reported no remaining BioXcel Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Profund Advisors sold 2,217 BioXcel Therapeutics shares in Q3 2023, an estimated $236K.
  • Profund Advisors first reported a position in BioXcel Therapeutics in Q1 2023 and held it in 2 quarters.
  • Profund Advisors's BioXcel Therapeutics position peaked at $512K in Q1 2023.
  • 85 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2023.

Based on Profund Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.